Zoetis (NYSE:ZTS) Issues FY 2025 Earnings Guidance

Zoetis (NYSE:ZTS) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 6.000-6.100 for the period, compared to the consensus EPS estimate of 6.300. The company issued revenue guidance of $9.2 billion-$9.4 billion, compared to the consensus revenue estimate of $9.6 billion.

Zoetis Stock Down 0.2 %

ZTS stock opened at $173.99 on Thursday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis has a 52-week low of $144.80 and a 52-week high of $200.53. The company has a 50-day moving average of $169.11 and a two-hundred day moving average of $179.11. The stock has a market capitalization of $78.50 billion, a price-to-earnings ratio of 32.70, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.15%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is presently 37.59%.

Analyst Upgrades and Downgrades

ZTS has been the subject of several research reports. Piper Sandler reduced their target price on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday. Morgan Stanley reduced their target price on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Leerink Partners initiated coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price for the company. Stifel Nicolaus reduced their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, UBS Group assumed coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Zoetis currently has an average rating of “Buy” and a consensus target price of $214.00.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.